Home › Research › Disparities
Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia
Mohini Johri, Valerie Morrill, Derrick N. Okine, Xuemei Huang, Liana S. Rosenthal, Joseph Seemiller, Srishti Shrestha, Kevin Sullivan et al.. Neurology, 2025-09-04
Topic: Risk, prevention and care in population studies
Plain-language summary
Among 13,875 individuals with nonmissing VRF and outcome data with up to 30 years of follow-up (25% Black, 54% female), 179 developed PD at a mean age of 73.4 years, 94 developed PDD at a mean age of 79.2 years, and 1,791 developed dementia without PD at a mean age of 79.7 years. Midlife current smoking (hazard ratio [HR] 0.36, 95% CI 0.21-0.61) was significantly associated with a lower PD rate, independent of other risk factors and demographics. Midlife current smoking was also significantly associated with a lower rate of PDD (HR 0.41, 95% CI 0.18-0.95). Other VRFs were not associated with either PD or PDD. Smoking status in midlife was associated with lower rates of PD and PDD, but other VRFs had no association with PD or PDD. Further studies should evaluate changes of these VRFs over the life course and explore mechanisms for the observed associations.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 13,875 participants. This longitudinal study found that midlife current smoking was associated with lower rates of Parkinson disease and Parkinson disease-dementia, while other midlife vascular risk factors were not associated with either. Reported effect size: HR 0.41.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Johri, M., Morrill, V., Okine, D. N., Huang, X., Rosenthal, L. S., Seemiller, J., et al. (2025). Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia. Neurology. https://doi.org/10.1212/wnl.0000000000213931
Vancouver
Johri M, Morrill V, Okine DN, Huang X, Rosenthal LS, Seemiller J, et al. Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia. Neurology. 2025. doi:10.1212/wnl.0000000000213931. PMID: 40906974.
BibTeX
@article{johri2025-40906974,
author = {Johri, Mohini and Morrill, Valerie and Okine, Derrick N. and Huang, Xuemei and Rosenthal, Liana S. and Seemiller, Joseph and Shrestha, Srishti and Sullivan, Kevin and others},
title = {{Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia}},
journal = {Neurology},
year = {2025},
doi = {10.1212/wnl.0000000000213931},
pmid = {40906974},
url = {https://doi.org/10.1212/wnl.0000000000213931}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Among 13,875 individuals with nonmissing VRF and outcome data with up to 30 years of follow-up (25% Black, 54% female), 179 developed PD at a mean age of 73.4 years, 94 developed PDD at a mean age of 79.2 years, and 1,791 developed dementia without PD at a mean age of 79.7 years.
- Midlife current smoking (hazard ratio [HR] 0.36, 95% CI 0.21-0.61) was significantly associated with a lower PD rate, independent of other risk factors and demographics.
- Midlife current smoking was also significantly associated with a lower rate of PDD (HR 0.41, 95% CI 0.18-0.95).
- Other VRFs were not associated with either PD or PDD.
- Smoking status in midlife was associated with lower rates of PD and PDD, but other VRFs had no association with PD or PDD.
Why it matters
This longitudinal study found that midlife current smoking was associated with lower rates of Parkinson disease and Parkinson disease-dementia, while other midlife vascular risk factors were not associated with either. The authors call for further studies to explore mechanisms for these observed associations, and the findings concern Parkinson disease rather than Alzheimer's disease treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Study designlongitudinal study
- Participants13,875
- Effect sizeHR 0.41
- Evidence strengthModerate
How this study scored 67/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 13,875 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Rebecca F. Gottesman: h-index 92 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | National Institutes of Health: institution h-index 2,723 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40906974) |
| Free to read | 2 / 2 | Free to read |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0000000000213931
- PubMed: 40906974
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disparities from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.